Alpha Centric Advisors LLC Arcutis Biotherapeutics, Inc. Transaction History

Alpha Centric Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$5.31 - $10.98 $677,025 - $1.4 Million	-127,500 Reduced 43.59%	165,000 $876,000
Q2 2023 Aug 08, 2023	BUY	$7.51 - $15.0 $769,775 - $1.54 Million	102,500 Added 53.95%	292,500 $2.79 Million
Q1 2023 May 12, 2023	BUY	$10.23 - $17.14 $1.14 Million - $1.91 Million	111,500 Added 142.04%	190,000 $2.09 Million
Q4 2022 Feb 07, 2023	BUY	$13.96 - $20.4 $1.1 Million - $1.6 Million	78,500 New	78,500 $1.16 Million
Q3 2022 Nov 08, 2022	SELL	$17.85 - $26.95 $937,125 - $1.41 Million	-52,500 Closed	0 $0

Q4 2021 Feb 25, 2022	BUY	$14.98 - $25.5 $254,660 - $433,500	17,000 Added 47.89%	52,500 $1.09 Million
Q3 2021 Mar 09, 2022	BUY	$19.28 - $27.1 $424,160 - $596,200	22,000 Added 162.96%	35,500 $848,000
Q2 2021 Mar 09, 2022	BUY	$24.42 - $34.75 $36,630 - $52,125	1,500 Added 12.5%	13,500 $368,000
Q1 2021 Mar 09, 2022	BUY	$24.47 - $36.98 $293,640 - $443,759	12,000 New	12,000 $347,000

172

126M

498K

1.64M

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $560M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.